Skip to main content

Table 3 Reasons for interruption of darunavir/cobicistat

From: Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)

  Dual therapy Triple therapy Total
N = 72 % N = 177 % N = 249 %
Adverse events 1 1.4 12 6.8 13 5.2
Simplification/proactive switch 1 1.4 14 7.9 15 6.0
Patient’s preference/low adherence 2 2.8 6 3.4 8 3.2
Therapeutic failure 2 2.8 0 0.0 2 0.8
Death 0 0.0 2 1.1 2 0.8
Drug-drug interaction 1 1.4 3 1.7 4 1.6
Other reasons 1 1.4 1 0.6 2 0.8
Lost to follow-up 8 11.1 18 10.2 26 10.4